BVF PARTNERS L P/IL - 05 Jun 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Signature
BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Issuer symbol
MLTX
Transactions as of
05 Jun 2025
Net transactions value
$0
Form type
4
Filing time
09 Jun 2025, 19:16:08 UTC
Previous filing
20 May 2025
Next filing
13 Jun 2025

Reporting Owners (10)

Name Relationship Address Signature Signature date CIK
BVF PARTNERS L P/IL Director, 10%+ Owner 44 MONTGOMERY ST., 40TH FL, SAN FRANCISCO BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 09 Jun 2025 0001055947
BIOTECHNOLOGY VALUE FUND L P Director, 10%+ Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 09 Jun 2025 0000918923
BVF I GP LLC Director, 10%+ Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 09 Jun 2025 0001803805
BIOTECHNOLOGY VALUE FUND II LP Director, 10%+ Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 09 Jun 2025 0001102444
BVF II GP LLC Director, 10%+ Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 09 Jun 2025 0001803806
Biotechnology Value Trading Fund OS LP Director, Other* P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 09 Jun 2025 0001660683
BVF Partners OS Ltd. Director, Other* P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 09 Jun 2025 0001660684
BVF GP HOLDINGS LLC Director, 10%+ Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 09 Jun 2025 0001803809
BVF INC/IL Director, 10%+ Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO BVF Inc., By: /s/ Mark N. Lampert, President 09 Jun 2025 0001056807
LAMPERT MARK N Director, 10%+ Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO /s/ Mark N. Lampert 09 Jun 2025 0001233840

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MLTX Class A Ordinary Shares, $0.0001 par value 10,235,089 05 Jun 2025 Direct F1, F2
holding MLTX Class A Ordinary Shares, $0.0001 par value 8,168,838 05 Jun 2025 Direct F1, F3
holding MLTX Class A Ordinary Shares, $0.0001 par value 1,287,768 05 Jun 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Option to Buy Award $0 +6,682 $0.000000 6,682 05 Jun 2025 Class A Ordinary Shares, $0.0001 par value 6,682 $48.83 See footnote F1, F5, F8
holding MLTX Option to Buy 7,688 05 Jun 2025 Class A Ordinary Shares, $0.0001 par value 7,688 $42.44 See footnote F1, F6, F8
holding MLTX Option to Buy 11,297 05 Jun 2025 Class A Ordinary Shares, $0.0001 par value 11,297 $29.18 See footnote F1, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F2 Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general parter of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
F3 Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
F4 Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
F5 This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to Spike Loy's continued service to the Issuer.
F6 This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer. This option has fully vested as of the date hereof.
F7 This option represents a right to purchase a total of 11,297 Class A Ordinary Shares of the Issuer. This option has fully vested as of the date hereof.
F8 Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Remarks:

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a Managing Director of Partners, Spike Loy, serving on the Board of Directors of the Issuer, and his agreement to transfer to Partners the economic benefit, if any, received upon the sale of any securities of the Issuer he receives in his capacity as a director of the Issuer.